This website is intended for UK healthcare professionals only
Prescribing information can be found here
About Invokana - Indication, Dosing & Cost
Invokana Mode of Action Icon

Mode of Action

How Invokana works

  • Invokana is an SGLT2 inhibitor (SGLT2i).
  • SGLT2 is a sodium-glucose cotransporter expressed in the proximal renal tubules, and is responsible for 90% of glucose reabsorption. 1,2

  • SGLT2is act independently of β-cell function or insulin sensitivity – removing excess blood glucose by increasing urinary glucose excretion. 3
  • This also results in a loss of excess calories and water – which is why Invokana also reduces both weight and blood pressure. 4,5
Weight loss and blood pressure reduction are additional benefits only and not licensed indications.

View mode of action video here:

An insulin independent approach to achieve glycaemic control

T2DM without Invokana

Click diagrams to enlarge

T2DM with Invokana

  • SGLT2is are responsible for 90% of glucose reabsorption1,2, making it an attractive target for inhibition.5

  • SGLT2is act independently of β-cell function or insulin sensitivity – removing excess blood glucose by increasing urinary glucose secretion.3 This also results in a loss of excess calories and water – which is why Invokana also reduces both weight and blood pressure.4,6

  • Invokana increases estimated urinary glucose secretion ranging from 77–119 g per day. This translates to an equivalent loss of 308-476 kcal/day 2. [Results from Phase I studies of urinary glucose excretion in patients with type 2 diabetes.]

This leads to:

  • Improved glycaemic control and a reduction in HbA1c. 2
  • A loss of calories and therefore a reduction in body weight. 2
  • A mild osmotic diuresis, with the diuretic effect leading to a reduction in systolic blood pressure. 2
Weight loss and blood pressure reduction are additional benefits only and not licensed indications.

How Invokana delivers renal benefits

  • In type 2 diabetes, SGLT2 is overexpressed – leading to glomerular hyperfiltration. Inhibiting SGLT2 may, therefore, reduce hyperfiltration and lead to decreases in intraglomerular pressure.7,8

References
  1. Bays H. Curr Med Res Opin 2009;25(3):671-81
  2. Reference 7
  3. Bailey CD et al. BMC Med 2013;11:43
  4. Rothenberg PL et al. European Association for the Study of Diabetes (EASD) Annual Meeting. Stockholm, Sweden 2016. Abstract No. 876 (poster)
  5. Dokken NP. Diabetes Spectrum 2012;25(8):29-36
  6. Lavalle-Gonzáles FJ, et al. Diabetologia 2013;56(12):2582-92
  7. Rahmoune H et al. Diabetes 2005;54:3427-34
  8. Fioretto P et al. Diabetes Care 2016;39(Suppl 2):S165-S171